|DB00008||Peginterferon alfa-2a||Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have
compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].|
|DB00022||Peginterferon alfa-2b||Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
|DB00059||Pegaspargase||For treatment of acute lymphoblastic leukemia|
|DB01563||Chloral hydrate||Mainly used as a hypnotic in the treatment of insomnia; however, it is only effective as a hypnotic for short-term use. May be used as a routine sedative preoperatively to decrease anxiety and cause sedation and/or sleep with respiration depression or cough reflex. |
|DB04682||Octylphenoxy polyethoxyethanol||Not Available|
|DB04978||SP1049C||Intended for the treatment of carcinoma of the oesophagus.|
|DB05321||PEG-uricase||Investigated for use/treatment in hyperuricemia.|
|DB05446||LJP 1082||Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.|
|DB05718||Maxy-G34||Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.|
|DB06439||Tyloxapol||Tyloxapol is an inhaled surfactant that assists in removing and liquefying and removing bronchopulmonary secretions with mucus and pus. Tyloxapol is administered either through nebulized solution or a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications.|
|DB06611||Pegsunercept||Investigated for use/treatment in rheumatoid arthritis.|
|DB06804||Nonoxynol-9||Nonoxynol 9 is a surfactant spermicide used for contraception in spermicidal creams, jellies, foams, gel, and lubricants. It is also used in conjuction with other methods of contraception, including condoms, cervical caps and diaphragms.|
|DB06811||Polidocanol||Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity. |
|DB08894||Peginesatide||Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis |
|DB08904||Certolizumab pegol||Certolizumab pegol has been approved for several different conditions listed below:
- Symptomatic management of Chron's disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy.
- Treatment of adult patients with moderate to severely active rheumatoid arthritis.
- Treatment of adult patients with active psoriatic arthritis.
- Treatment of adult patients with active ankylosing spondylitis.
- Treatment of adult patients with moderate-to-severe plaque psoriasis that are candidates for systemic therapy or phototherapy.[FDA label]
- Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.[L5819]
In Canada, certolizumab pegol is additionally approved in combination with [methotrexate] for the symptomatic treatment, including major clinical response, and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritis.[L5825]
Inflammation is a biological response against a potential threat. This response can be normal but in certain conditions, the immune system can attack the body's normal cells or tissues which causes an abnormal inflammation.[L5840] TNF-alpha has been identified as a key regulator of the inflammatory response. The signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death, survival, differentiation, proliferation and migration.[A176660] |
|DB09049||Naloxegol||Indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.|
|DB09107||Methoxy polyethylene glycol-epoetin beta||For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.|
|DB09122||Peginterferon beta-1a||For the treatment of patients with relapsing forms of multiple sclerosis.|
|DB09208||Pegloticase||For the treatment of chronic gout in adult patients refractory to conventional therapy.|
|DB09287||Polyethylene glycol||Used to treat and prevent constipation.|
|DB11063||Polysorbate 80||It is used as a solubilizer, antimicrobial preservative and disinfectant [L1853].|
|DB11077||Polyethylene glycol 400||PEG-400 has been indicated for the temporary relief of burning and irritation due to dryness of the eye, and
for protection against further irritation and desiccation [L1795], [L1796], [L1797].|
|DB11161||Polyethylene glycol 300||Indicated as a lubricant in over-the-counter ophthalmic solutions to temporarily relieve redness, burning and irritation of the eyes.|
|DB11178||Polysorbate 20||Not Available|
|DB11252||Poloxamer 407||Not Available|
|DB11333||Poloxamer 188||Indicated to reduce viscosity in the blood before transfusions. |
|DB11567||Insulin peglispro||Not Available|
|DB11635||Tocofersolan||Tocofersolan is indicated in vitamin E deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth (full term newborns) up to 18 years of age [L2371].|
|DB13933||Nonacog beta pegol||Nonacog beta pegol is indicated for the use in adults and children with hemophilia B for control and prevention of bleeding episodes, routine prophylaxis and perioperative management.[L1100] In the EMA approval, it is also indicated for on-demand treatment of bleeding episodes.[L1099] Hemophilia B is characterized by a deficiency in the coagulation factor IX which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing. Hemophilia B patients present more frequent bleeding episodes during childhood and adolescence than in adulthood.[T56]|
|DB09329||Antihemophilic Factor (Recombinant), PEGylated||For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], [A32064].
This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease [FDA label].|
|DB02327||Triethylene glycol||Not Available|
|DB14730||Calaspargase pegol||This drug is is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years [FDA label].
The pharmacokinetics of calaspargase pegol were examined when given in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL [L4890]. The FDA approval of this drug was based on the achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL when administering calaspargase, 2500 U/m2 intravenously, at 3-week intervals. |
|DB06592||Pegargiminase||Investigated for use/treatment in melanoma and hepatocellular carcinoma.|
|DB14767||Peginterferon lambda-1a||Not Available|
|DB14951||Etirinotecan pegol||Not Available|
|DB14953||Firtecan pegol||Not Available|
|DB15112||Somatropin pegol||Not Available|
|DB15441||Lulizumab pegol||Not Available|